|
Sponsor
|
Postings ↑
|
Description
|
Created
|
| |
|
Clinical Studies focused on using IDP-431d in non-standard indications
|
We are interested in clinical studies that would like to use IDP-431d in non-standard/approved indications. A little lorem ipsum dolor sit amet, consectetur adipiscing elit, sed do eiusmod tempor incididunt ut labore et dolore magna aliqua. Ut enim ad minim veniam, quis nostrud exercitation ullamco laboris nisi ut aliquip ex ea commodo consequat.
Duis aute irure dolor in reprehenderit in voluptate velit esse cillum dolore eu fugiat nulla pariatur. Excepteur sint occaecat cupidatat non proident, sunt in culpa qui officia deserunt mollit anim id est laborum. Semper eget duis at tellus at urna. Eu nisl nunc mi ipsum faucibus. Nulla aliquet enim tortor at auctor urna nunc. Sit amet mauris commodo quis imperdiet massa tincidunt. Nunc scelerisque viverra mauris in aliquam sem fringilla ut. Mattis molestie a iaculis at. Dolor morbi non arcu risus quis varius quam.
|
12/18/2020
|
| |
|
FAK Inhibition Program
|
We are interested in requests related to FAK Inhibition Program. Expression of focal adhesion kinase (FAK) is greater in many tumor types as compared to normal tissue, particularly in cancers that have high invasive and metastatic capability. FAK has many kinase-dependent functions, including control of cell movement, invasion, survival and gene expression.
|
9/15/2019
|
| |
|
PI3K Inhibition (delta, gamma) Program
|
We are interested in requests related to PI3K Inhibition. The phosphoinositide 3-kinase (PI3K) signaling pathway is a key regulator in cancer proliferation (rapid increase or spread) and metastasis (development of secondary growths away from a primary site of cancer). The PI3K pathway includes four Class I isoforms: alpha, beta, delta and gamma (α, β, δ, and γ). The four isoforms play unique roles in the survival of different tumor types and in the creation of supportive tumor microenvironments.
|
9/15/2019
|
Just a moment, the page is loading...